Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

FLC testing in multiple myeloma and kidney disease: An American Perspective

Multiple myeloma (MM) is one of the most common blood cancers, often involving impaired kidney function. Free light chains (FLC) testing is a guideline-recommended cornerstone in the diagnosis, monitoring, and disease management of MM. This session explores the current role of FLC testing in MM, and considers the influence of kidney function on FLC test result. Dr. Zaydman shares an American perspective on this important subject.

Mark Zaydman, Washington University Phycisians

Dr. Mark Zaydman
Department of Pathology and Immunology
Division of Laboratory and Genomic Medicine
Washington University Physicians, USA